Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study - Mall,MA; Wainwright,CE; Legg,J; Chilvers,M; Gartner,S; Dittrich,A-M; Stehling,F; Conner,S; Grant,S; Suresh,N; Weinstock,TG; Davies,JC (EUROPEAN RESPIRATORY JOURNAL, 2025)